CellWell record HH-285756
Comparative cost-effectiveness analysis of therapy with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and high cardiovascular risk or a history of atherosclerotic cardiovascular diseases in the Russian healthcare system
M. V. Zhuravleva; Yu. V. Gagarina; T. V. Marin; O. Kapto
Russian Journal of Cardiology ยท 2026
In plain language
SGLT2 inhibitors cost less than half of GLP-1 agonists annually for cardiovascular risk reduction in type 2 diabetes with comparable clinical efficacy.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-285756
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.